Latest Oncosil Medical News

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.

OncoSil Medical’s CEO Nigel Lange has agreed to a 10% salary reduction, opting instead to receive shares at a significant premium, reinforcing executive commitment to shareholder value and cost discipline.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

OncoSil Medical’s interim OSPREY registry data reveals promising survival improvements for patients with unresectable locally advanced pancreatic cancer treated with OncoSil™ plus chemotherapy. The findings suggest a meaningful step forward in a field with limited effective options.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

OncoSil Medical Limited has addressed ASX concerns over delayed disclosure of PANCOSIL clinical trial results, confirming compliance with continuous disclosure obligations despite procedural oversights.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

OncoSil Medical’s PANCOSIL Phase 1-2 study reveals promising safety and feasibility for a novel CT-guided pancreatic cancer therapy, with survival outcomes exceeding historical benchmarks.

OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.